In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Rising Leaders Leadership

30 Life Sciences Leaders To Watch In 2021

  • News

Executive Summary

30 Rising Leaders who are making waves and challenging traditional structures across the biopharma and medtech sectors. In Vivo's 2021 list also includes industry stars that have raised their game in response to the COVID-19 pandemic. 

You may also be interested in...



Effective Integration Is The Key To BD Success For Ipsen

At the 2023 BIO-Europe conference, In Vivo sat down with Ipsen’s EVP and chief business officer, Philippe Lopes-Fernandes, to discuss the company’s business development strategy and future goals.

Scrip 100: By The Numbers

Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.

Outlook 2024: Biopharma Embraces New Markets And New Tech

New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024? 

Table

View full table

Topics

Tags:
Commercial Rising Leaders Leadership
Latest Headlines

The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now

Effective Integration Is The Key To BD Success For Ipsen

Scrip 100: By The Numbers

Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way

See All
UsernamePublicRestriction

Register

IV124787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By